Trinity Biotech provides business update; reports Q1 highlights, now expects to be adjusted EBITDA-positive starting in Q3 2025 and into the foreseeable future ($0.65, 0.00)
Trinity Biotech secures WHO approval for offshored and outsourced manufacturing of its flagship rapid HIV test ($0.55, 0.00)
Trinity Biotech reports Q4 EPS ($1.28) vs year-ago $0.72 ($0.84, 0.00)
Trinity Biotech appoints Barclays as financial advisor to support its ongoing strategic realignment ($0.68, 0.00)
Trinity Biotech obtains additional $4M in debt financing from primary lender Perceptive Advisors ($0.75, 0.00)
Trinity announces new findings from its latest pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system ($0.86, 0.00)
Trinity Biotech provides update on potential impacts of US Executive Order on Foreign Aid around the company's rapid HIV testing - 6-K ($1.32, 0.00)
Trinity Biotech announces results from pre-pivotal trial of disruptive continuous glucose monitoring (CGM) technology ($0.76, 0.00)
Trinity Biotech amends credit agreement ($0.90, 0.00)
Trinity Biotech receives early approval from WHO to begin offshore manufacturing of TrinScreen HIV & Uni-Gold HIV ($0.83, -0.02)
Powered by FactSet Research Systems Inc.